Biocomposites has launched its SYNICEM antibiotic-loaded preformed spacers in Canada, expanding access to the company’s hip, knee and shoulder devices for use in two-stage revision procedures following prosthetic joint infection.

SYNICEM spacers are designed to preserve joint space, limb length and stability during revision surgery while delivering gentamicin to help treat bacterial infection. The preformed devices are supplied sterile and ready to use, aiming to reduce operative time and the mechanical variability associated with intra-operative moulded or handmade spacers.

The range includes Charnley and Müller hip spacer designs, as well as left and right geometries for knee procedures, and is available in multiple sizes to support surgeon choice on a case-by-case basis. Biocomposites said the spacers have been used for more than 20 years in over 70 countries.

Michael Harris, ceo of Biocomposites, said: “Making SYNICEM preformed antibiotic loaded spacers available to surgeons in Canada, less than three months after launching them in the U.S., is a source of pride for the team at Biocomposites. The quality and consistency of the SYNICEM spacer range reflects our long-standing focus on precision engineering and dependable performance, with the aim of supporting clinicians and improving care for patients with complex needs.”

Prosthetic joint infection remains a major complication of orthopaedic surgery, often requiring a two-stage revision procedure. In this approach, the infected implant is removed and replaced with an antibiotic-loaded spacer before a new prosthesis is implanted once infection is controlled. Spacers can help maintain joint function and mobility while delivering high local antibiotic concentrations, but intra-operative preparation can be time-consuming and technically variable.

Preformed spacers are intended to address some of these challenges by offering consistent geometry and mechanical properties, potentially reducing surgical time and variability between cases. Biocomposites said the devices are designed to support infection management in bone and soft tissue, an area where treatment failures can lead to prolonged hospitalisation, repeat surgeries and increased healthcare costs.

The Canadian launch follows a recent US introduction of the SYNICEM range, as the company expands its orthopaedic infection management portfolio in North America. Biocomposites did not disclose regulatory or commercial details for other geographies.

The company develops and manufactures medical devices for infection management in orthopaedic and soft tissue procedures, and has focused on antibiotic delivery systems and bone void fillers.